Treatment of genitourinary carcinoma in dogs using nonsteroidal anti‐inflammatory drugs, mitoxantrone, and radiation therapy: A retrospective study
Abstract Background Locoregional tumor control and prolonged survival for dogs with genitourinary carcinoma (CGUC) reportedly are achievable using treatment with radiotherapy (RT) with or without adjunctive chemotherapy and nonsteroidal anti‐inflammatory drugs (NSAIDs). Objectives To characterize ev...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-03-01
|
Series: | Journal of Veterinary Internal Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1111/jvim.16078 |
id |
doaj-af5be1148f234f188d592293a84fa2d3 |
---|---|
record_format |
Article |
spelling |
doaj-af5be1148f234f188d592293a84fa2d32021-03-26T10:53:09ZengWileyJournal of Veterinary Internal Medicine0891-66401939-16762021-03-013521052106110.1111/jvim.16078Treatment of genitourinary carcinoma in dogs using nonsteroidal anti‐inflammatory drugs, mitoxantrone, and radiation therapy: A retrospective studyBenoit Clerc‐Renaud0Tracy L. Gieger1Susan M. LaRue2Michael W. Nolan3Flint Animal Cancer Center Colorado State University Fort Collins Colorado USADepartment of Clinical Sciences, College of Veterinary Medicine North Carolina State University Raleigh North Carolina USAFlint Animal Cancer Center Colorado State University Fort Collins Colorado USADepartment of Clinical Sciences, College of Veterinary Medicine North Carolina State University Raleigh North Carolina USAAbstract Background Locoregional tumor control and prolonged survival for dogs with genitourinary carcinoma (CGUC) reportedly are achievable using treatment with radiotherapy (RT) with or without adjunctive chemotherapy and nonsteroidal anti‐inflammatory drugs (NSAIDs). Objectives To characterize event‐free and overall survival after treatment of CGUC using NSAIDs, mitoxantrone (MTX), and a standardized RT protocol (57 Gy in 20 fractions). Animals Fifty‐one client‐owned dogs treated between 2008 and 2017. Methods Dogs were retrospectively categorized into treatment groups: (a) first‐line concurrent chemoradiotherapy (≥1 dose of MTX started within 1 month of RT); (b) first‐line chemotherapy (MTX administered for >1 month before RT without tumor progression); (c) RT as a salvage procedure (MTX, surgery or both with subsequent locoregional tumor progression before RT). Treatment‐induced toxicoses, event‐free survival (EFS), and overall survival times (OSTs) were recorded. The influence of demographics, staging, and treatment‐related factors on survival was assessed using Cox proportional hazards modeling. Results Median EFS and OST for all dogs were 260 and 510 days with no significant differences among groups 1 (n = 39), 2 (n = 4), and 3 (n = 8). Both EFS and OST were shorter in dogs with moderate to severe clinical signs (P < .001 and P < .001, respectively); OST was shorter in dogs with prostatic involvement (P = .02). Permanent urinary incontinence developed in 16 dogs (31%) at a median of 70 days postirradiation; other toxicoses were mild and self‐limiting. Conclusions and Clinical Importance Mild clinical signs and lack of prostate involvement were associated with favorable prognosis for survival. Client education regarding the risk of urinary incontinence is warranted.https://doi.org/10.1111/jvim.16078definitive‐intentdogsintensity‐modulatedradiotherapyurogenital carcinoma |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Benoit Clerc‐Renaud Tracy L. Gieger Susan M. LaRue Michael W. Nolan |
spellingShingle |
Benoit Clerc‐Renaud Tracy L. Gieger Susan M. LaRue Michael W. Nolan Treatment of genitourinary carcinoma in dogs using nonsteroidal anti‐inflammatory drugs, mitoxantrone, and radiation therapy: A retrospective study Journal of Veterinary Internal Medicine definitive‐intent dogs intensity‐modulated radiotherapy urogenital carcinoma |
author_facet |
Benoit Clerc‐Renaud Tracy L. Gieger Susan M. LaRue Michael W. Nolan |
author_sort |
Benoit Clerc‐Renaud |
title |
Treatment of genitourinary carcinoma in dogs using nonsteroidal anti‐inflammatory drugs, mitoxantrone, and radiation therapy: A retrospective study |
title_short |
Treatment of genitourinary carcinoma in dogs using nonsteroidal anti‐inflammatory drugs, mitoxantrone, and radiation therapy: A retrospective study |
title_full |
Treatment of genitourinary carcinoma in dogs using nonsteroidal anti‐inflammatory drugs, mitoxantrone, and radiation therapy: A retrospective study |
title_fullStr |
Treatment of genitourinary carcinoma in dogs using nonsteroidal anti‐inflammatory drugs, mitoxantrone, and radiation therapy: A retrospective study |
title_full_unstemmed |
Treatment of genitourinary carcinoma in dogs using nonsteroidal anti‐inflammatory drugs, mitoxantrone, and radiation therapy: A retrospective study |
title_sort |
treatment of genitourinary carcinoma in dogs using nonsteroidal anti‐inflammatory drugs, mitoxantrone, and radiation therapy: a retrospective study |
publisher |
Wiley |
series |
Journal of Veterinary Internal Medicine |
issn |
0891-6640 1939-1676 |
publishDate |
2021-03-01 |
description |
Abstract Background Locoregional tumor control and prolonged survival for dogs with genitourinary carcinoma (CGUC) reportedly are achievable using treatment with radiotherapy (RT) with or without adjunctive chemotherapy and nonsteroidal anti‐inflammatory drugs (NSAIDs). Objectives To characterize event‐free and overall survival after treatment of CGUC using NSAIDs, mitoxantrone (MTX), and a standardized RT protocol (57 Gy in 20 fractions). Animals Fifty‐one client‐owned dogs treated between 2008 and 2017. Methods Dogs were retrospectively categorized into treatment groups: (a) first‐line concurrent chemoradiotherapy (≥1 dose of MTX started within 1 month of RT); (b) first‐line chemotherapy (MTX administered for >1 month before RT without tumor progression); (c) RT as a salvage procedure (MTX, surgery or both with subsequent locoregional tumor progression before RT). Treatment‐induced toxicoses, event‐free survival (EFS), and overall survival times (OSTs) were recorded. The influence of demographics, staging, and treatment‐related factors on survival was assessed using Cox proportional hazards modeling. Results Median EFS and OST for all dogs were 260 and 510 days with no significant differences among groups 1 (n = 39), 2 (n = 4), and 3 (n = 8). Both EFS and OST were shorter in dogs with moderate to severe clinical signs (P < .001 and P < .001, respectively); OST was shorter in dogs with prostatic involvement (P = .02). Permanent urinary incontinence developed in 16 dogs (31%) at a median of 70 days postirradiation; other toxicoses were mild and self‐limiting. Conclusions and Clinical Importance Mild clinical signs and lack of prostate involvement were associated with favorable prognosis for survival. Client education regarding the risk of urinary incontinence is warranted. |
topic |
definitive‐intent dogs intensity‐modulated radiotherapy urogenital carcinoma |
url |
https://doi.org/10.1111/jvim.16078 |
work_keys_str_mv |
AT benoitclercrenaud treatmentofgenitourinarycarcinomaindogsusingnonsteroidalantiinflammatorydrugsmitoxantroneandradiationtherapyaretrospectivestudy AT tracylgieger treatmentofgenitourinarycarcinomaindogsusingnonsteroidalantiinflammatorydrugsmitoxantroneandradiationtherapyaretrospectivestudy AT susanmlarue treatmentofgenitourinarycarcinomaindogsusingnonsteroidalantiinflammatorydrugsmitoxantroneandradiationtherapyaretrospectivestudy AT michaelwnolan treatmentofgenitourinarycarcinomaindogsusingnonsteroidalantiinflammatorydrugsmitoxantroneandradiationtherapyaretrospectivestudy |
_version_ |
1724202170885079040 |